What does Semax (Intranasal) stack well with?

For metabolic / endocrine protocols, Semax (Intranasal) pairs with compounds on complementary pathways: Semaglutide (GLP-1), Cagrilintide, MOTS-c. These pairings are selected because they engage independent receptor systems from Semax (Intranasal)'s primary mechanism (Same Semax; olfactory delivery preferred), producing additive or synergistic effects rather than receptor competition.

What is the evidence base for Semax (Intranasal)?

Semax (Intranasal)'s evidence base sits at research level investigational. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The metabolic / endocrine interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What is Semax (Intranasal)?

Semax (Intranasal) (also known as Intranasal Semax) is a 7-residue acth-derived nootropic heptapeptide (intranasal) with a molecular weight of 813 Da and a plasma half-life of CNS effect hours. Same Semax; olfactory delivery preferred. The compound is studied primarily in the metabolic / endocrine domain for the applications outlined above.

How does Semax (Intranasal) affect glycemic and metabolic markers?

Semax (Intranasal)'s metabolic effects depend on whether it engages the incretin-amylin axis directly or operates through inflammation, mitochondrial, or adiposity pathways. Effects on glycemic markers tend to be gradual and operate through metabolic flexibility, inflammation reduction, and adiposity changes. Baseline HbA1c, fasting insulin, and — ideally — CGM during the first cycle clarify individual response.

What are the safety considerations for Semax (Intranasal)?

Excellent. For metabolic and glycemic use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Semax (Intranasal)'s CNS effect hours pharmacokinetic profile and intranasal administration route influence the side-effect profile in predictable ways.

What is the regulatory status of Semax (Intranasal)?

Semax (Intranasal) regulatory status: Unapproved (Russia approved) in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For metabolic and glycemic use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Home/ Compounds/ Semax (Intranasal)

Semax (Intranasal)

Metabolic

Metabolic-medicine specialists evaluate Semax (Intranasal) against glycemic control, insulin sensitivity, visceral adiposity, and the broader cardiometabolic risk profile. Same Semax; olfactory delivery preferred. Baseline labs (HbA1c, fasting glucose, fasting insulin, HOMA-IR, lipid panel, ALT/AST, hsCRP) with 6-8 week follow-up on the 300-1000 mcg per dose 2-4x daily for 10-14 day courses protocol provide the clinical evaluation framework.

Metabolic / Endocrine Applications

Weight ManagementVisceral Fat ReductionGLP-1 SynergyFatty Liver ResearchMetabolic Syndrome

Key Takeaways

Metabolic lens: Semax (Intranasal) is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers.
Mechanism: Same Semax; olfactory delivery preferred.
Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle.
Metabolic dose: 300-1000 mcg per dose 2-4x daily for 10-14 day courses via intranasal.
Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.

Metabolic / Endocrine Mechanism

Same Semax; olfactory delivery preferred. The metabolic medicine framework evaluates Semax (Intranasal) against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.

Visceral fat and the cardiometabolic axis

Semax (Intranasal)'s effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.

AMPK and mitochondrial signalling

Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. Semax (Intranasal) engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.

Insulin signalling and glycemic effect

Semax (Intranasal)'s relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.

Metabolic / Endocrine Applications

GLP-1 Synergy

In the metabolic syndrome population, Semax (Intranasal) for glp-1 synergy produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

Liver Metabolism

Where Semax (Intranasal) is used for liver metabolism, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.

Weight Management

Semax (Intranasal) for weight management is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.

Visceral Fat Reduction

In the metabolic syndrome population, Semax (Intranasal) for visceral fat reduction produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300-1000 mcg per dose	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180-1000 mcg per dose	4–6 weeks initial cycle
Metabolic focus	Intranasal	300-1000 mcg per dose	2-4x daily for 10-14 day courses
Maintenance phase	Intranasal	210-1000 mcg per dose	Ongoing with periodic pauses

Dose timing for Semax (Intranasal) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Semax (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.

Semax (Intranasal) + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with Semax (Intranasal)'s mechanism in metabolic / endocrine protocols.
Semax (Intranasal) + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with Semax (Intranasal)'s mechanism in metabolic / endocrine protocols.
Semax (Intranasal) + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Semax (Intranasal)'s mechanism in metabolic / endocrine protocols.
Semax (Intranasal) + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with Semax (Intranasal)'s mechanism in metabolic / endocrine protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (Russia approved)

Excellent.

Lens-specific safety considerations for metabolic / endocrine use of Semax (Intranasal): Excellent. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Semax in stroke recovery

PMID 21643748

Semax (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
Semax (Intranasal)	ACTH-derived nootropic heptapeptide (intranasal)	CNS effect hours	Metabolic
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding
Cagrilintide	Long-acting amylin analogue	~7 days	A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction

Frequently Asked Questions

Will Semax (Intranasal) affect my muscle mass during weight loss?

Aggressive weight loss without adequate protein intake and resistance training results in significant lean-mass loss with most metabolic compounds, including Semax (Intranasal). Pairing the metabolic protocol with 1.6–2.0 g/kg/day protein and twice-weekly resistance training preserves lean mass during the cut. This is now standard of care in metabolic medicine clinics.

Pancreatitis or thyroid risk?

Where Semax (Intranasal) engages the GLP-1 or GIP pathway, pancreatitis is a rare but serious adverse event warranting vigilance for severe persistent abdominal pain. Medullary thyroid carcinoma and MEN-2 syndrome are formal contraindications for GLP-1-class compounds based on rodent C-cell hyperplasia findings. Other compound classes do not carry these specific concerns.

Will I regain weight after stopping Semax (Intranasal)?

For most compounds in this class, partial weight regain after discontinuation is the typical pattern unless dietary and activity inputs have been fundamentally changed during the cycle. Metabolic-medicine practice increasingly frames peptide therapy as chronic rather than time-limited for weight management indications.

How does Semax (Intranasal) affect glycemic control?

Semax (Intranasal)'s effect on glycemic markers depends on its primary mechanism. Direct incretin and amylin agonists produce rapid and substantial shifts in fasting glucose and post-prandial response; compounds engaging insulin sensitivity indirectly produce more gradual shifts. Baseline HbA1c and — ideally — a CGM in the first cycle clarifies the individual response.

How should Semax (Intranasal) be stored and reconstituted?

Lyophilised Semax (Intranasal) stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

How long until I see results from Semax (Intranasal)?

Acute effects from Semax (Intranasal) appear within hours of dosing for receptor-level changes. metabolic and glycemic endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Clinical Protocol

Start a Semax (Intranasal) Protocol

Alukard provides physician-supervised metabolic protocols with GMP-certified Semax (Intranasal) and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get Protocol

Quick Facts

Molecular weight: 813 Da
Sequence length: 7 aa
Half-life: CNS effect hours
WADA: Not on prohibited list
FDA: Unapproved (Russia approved)

Stack Partners

Semaglutide (GLP-1)

Cagrilintide

MOTS-c

Tesamorelin

AOD-9604

Research Note

All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semax (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised metabolic protocols

Start Your Metabolic / Endocrine Protocol for Semax (Intranasal)

Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised